VolitionRx Limited announced a senior secured convertible promissory note with a principal amount of $2.4 million, backed by the company’s assets, and a five‑year common‑stock purchase warrant that allows the holder to buy up to 7,000,350 shares at an exercise price of $0.5714 per share. The note will be repaid in eighteen monthly installments of $133,333 beginning six months after issuance, with an option for the investor to increase payments up to $1 million in two installments. The warrant is convertible into common stock at the same price, giving the investor the opportunity to participate in future equity upside.
The financing follows a prior $7.5 million note issued in May 2025 to the same investor and includes a $70,000 commitment fee that is deducted from the proceeds. The company plans to use the net proceeds to accelerate the commercialization of its Nu.Q platform, including ongoing clinical studies and the expansion of distribution partnerships in the human diagnostics market. The transaction strengthens VolitionRx’s balance sheet at a time when the company’s overall financial health score remains weak, reflecting its continued reliance on convertible financing to fund growth.
VolitionRx’s pipeline remains a key driver of investor interest. The company has recently announced breakthrough clinical data for its Nu.Q Vet Feline assay, which achieved over 80 % accuracy in detecting lymphoma with 100 % specificity. In addition, the Nu.Q Cancer assays have received their first order for clinical certification, and the Nu.Q NETs assays have been incorporated into a French government‑backed program for early sepsis detection. These milestones underscore the company’s dual focus on veterinary and human diagnostics and support the rationale for the new capital raise.
Management emphasized the strategic importance of the financing. President and CEO Cameron Reynolds said the company is “focused on commercializing our Nu.Q® platform in the human diagnostics market and is in confidential discussions with more than ten potential partners.” Frédéric Wuilque, VP‑Global Products, added that the company’s veterinary assays “are now a routine part of annual wellness checks for pets, and the success in cats demonstrates the technology’s broad applicability.”
The announcement was met with a positive market reaction, reflecting investor confidence in VolitionRx’s progress on its product pipeline and its ability to secure favorable financing terms. The transaction signals that the company’s management is actively pursuing growth opportunities while managing cash flow through convertible instruments.
The new financing provides VolitionRx with additional capital to support its commercialization strategy and to maintain momentum in both veterinary and human diagnostics. While the company remains in an early‑stage growth phase and continues to rely on convertible debt, the deal strengthens its balance sheet and positions it to capitalize on upcoming regulatory approvals and market opportunities.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.